These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 36436442)

  • 21. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials.
    Alhazzani W; Lim W; Jaeschke RZ; Murad MH; Cade J; Cook DJ
    Crit Care Med; 2013 Sep; 41(9):2088-98. PubMed ID: 23782973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 23. Current use of low molecular weight heparins.
    Donayre CE
    Semin Vasc Surg; 1996 Dec; 9(4):362-71. PubMed ID: 8958613
    [No Abstract]   [Full Text] [Related]  

  • 24. Summaries for patients. Low-molecular-weight heparin given for several weeks after hip surgery prevents deep venous thrombosis.
    Ann Intern Med; 2001 Nov; 135(10):S-55. PubMed ID: 11757493
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-molecular-weight heparin therapy in children.
    Massicotte MP
    J Pediatr Hematol Oncol; 2001; 23(3):189-94. PubMed ID: 11305725
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
    Brener SJ
    Cleve Clin J Med; 2000 Jan; 67(1):59-65. PubMed ID: 10645678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical review of the efficacy and safety in the use of low-molecular-weight heparin in acute ST-elevation myocardial infarction: a Bayesan approach.
    Buccelletti E; Spadaccio C; Chello M; Marsiliani D; Carroccia A; Iacomini P; Calabrò G; Gentiloni Silveri N; Franceschi F
    Eur Rev Med Pharmacol Sci; 2011 Jun; 15(6):701-10. PubMed ID: 21796875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van der Heijden JF; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK; Wang JJ
    Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
    Zarychanski R; Abou-Setta AM; Kanji S; Turgeon AF; Kumar A; Houston DS; Rimmer E; Houston BL; McIntyre L; Fox-Robichaud AE; Hébert P; Cook DJ; Fergusson DA;
    Crit Care Med; 2015 Mar; 43(3):511-8. PubMed ID: 25493972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?
    Spyropoulos AC
    Clin Cornerstone; 2005; 7(4):39-48. PubMed ID: 16758651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparin in outpatient treatment of DVT.
    Yeager BF; Matheny SC
    Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Crawford F
    Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
    Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
    Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The optimal long-term treatment of venous thromboembolism.
    Prandoni P
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):729-32. PubMed ID: 16170889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.